MarketCap
Facebook
X
TelegramAnnual report 2024
added 12-13-2025
Kamada Ltd. General and Administrative Expenses 2011-2025 | KMDA
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses Kamada Ltd.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 12.6 M | 9.36 M | 9.22 M | 7.84 M | 7.62 M | 6.64 M | 6.52 M | 7.1 M | 9.5 M | 4.41 M | 4.82 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 12.6 M | 4.41 M | 7.79 M |
General and Administrative Expenses of other stocks in the Biotechnology industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
ARCA biopharma
ABIO
|
13.1 M | - | 1052.0 % | $ 415 M |  USA |
 |
Amphastar Pharmaceuticals
AMPH
|
56.7 M | $ 25.27 | -2.43 % | $ 1.22 B | USA |
 |
MorphoSys AG
MOR
|
78.3 M | - | 2.43 % | $ 254 M |  Germany |
 |
Alpine Immune Sciences
ALPN
|
18 M | - | - | $ 2.17 B | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
22.5 M | $ 4.75 | 1.61 % | $ 788 M |  Canada |
 |
Aclaris Therapeutics
ACRS
|
22.2 M | $ 3.26 | -3.12 % | $ 252 M | USA |
 |
AlloVir
ALVR
|
42.9 M | - | 4.14 % | $ 49.1 M | USA |
 |
Acasti Pharma
ACST
|
7.17 M | - | 4.01 % | $ 150 M | Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
73.5 M | - | -15.15 % | $ 60.3 M |  Britain |
 |
Ampio Pharmaceuticals
AMPE
|
7.08 M | - | -11.43 % | $ 502 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
45.8 M | - | - | $ 1.01 B | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
1.4 B | - | - | $ 40.3 B | USA |
 |
Ascendis Pharma A/S
ASND
|
160 M | $ 220.27 | 4.81 % | $ 5 B |  Danmark |
 |
Albireo Pharma
ALBO
|
69.6 M | - | -0.23 % | $ 916 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
1.53 M | - | - | $ 7.46 M |  Israel |
 |
Enlivex Therapeutics Ltd.
ENLV
|
232 K | $ 0.91 | -5.01 % | $ 18.7 M | Israel |
 |
Can-Fite BioPharma Ltd.
CANF
|
3.05 M | $ 0.28 | -2.28 % | $ 609 M | Israel |
 |
Alterity Therapeutics Limited
ATHE
|
5.51 M | $ 3.3 | -3.51 % | $ 7.94 B |  Australia |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
4.66 M | - | -1.52 % | $ 24.7 M | USA |
 |
AstraZeneca PLC
AZN
|
15.2 B | $ 89.78 | -0.57 % | $ 96.9 B | Britain |
 |
Midatech Pharma plc
MTP
|
4.95 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Anika Therapeutics
ANIK
|
95.8 M | $ 9.57 | 0.84 % | $ 140 M | USA |
 |
Brickell Biotech
BBI
|
11.2 M | - | -5.38 % | $ 6.06 M | USA |
 |
BeiGene, Ltd.
BGNE
|
1.83 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Bellicum Pharmaceuticals
BLCM
|
5.72 M | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
95.1 M | - | -7.31 % | $ 87 M | USA |
 |
Benitec Biopharma
BNTC
|
6.97 M | $ 12.05 | -7.06 % | $ 496 M | USA |
 |
Aytu BioScience
AYTU
|
17.4 M | $ 2.34 | 2.59 % | $ 14.7 M | USA |
 |
Nymox Pharmaceutical Corporation
NYMX
|
5.85 M | - | -19.68 % | $ 18.4 M | Canada |
 |
Arena Pharmaceuticals
ARNA
|
126 M | - | -6.81 % | $ 3.04 B | USA |
 |
Aptorum Group Limited
APM
|
5.41 M | $ 1.29 | -3.01 % | $ 7.03 M |  China |
 |
Biophytis SA
BPTS
|
7.15 M | - | -13.47 % | $ 169 M |  France |
 |
Baudax Bio
BXRX
|
24.1 M | - | 0.59 % | $ 63 K | USA |
 |
Avenue Therapeutics
ATXI
|
4.64 M | - | -52.27 % | $ 4.45 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
25.8 M | - | - | - |  Russia |
 |
Catalyst Biosciences
CBIO
|
14.7 M | $ 14.01 | -8.49 % | $ 922 M | USA |
 |
ChromaDex Corporation
CDXC
|
18.4 M | - | -0.88 % | $ 598 M | USA |
 |
Axon Enterprise
AXON
|
741 M | $ 566.18 | -2.56 % | $ 42.9 B | USA |
 |
Cerus Corporation
CERS
|
75.9 M | $ 2.16 | 0.47 % | $ 399 M | USA |
 |
Checkpoint Therapeutics
CKPT
|
20.1 M | - | - | $ 169 M | USA |
 |
Caladrius Biosciences
CLBS
|
12.1 M | - | -16.75 % | $ 25.8 M | USA |
 |
Clovis Oncology
CLVS
|
128 M | - | -7.23 % | $ 13 M | USA |
 |
Biogen
BIIB
|
2.4 B | $ 174.42 | 1.11 % | $ 25.4 B | USA |
 |
BioVie
BIVI
|
8.57 M | $ 1.42 | -5.96 % | $ 2.1 M | USA |
 |
Celldex Therapeutics
CLDX
|
38.5 M | $ 27.36 | -2.09 % | $ 1.76 M | USA |
 |
Cortexyme
CRTX
|
17.7 M | - | -1.05 % | $ 67.1 M | USA |
 |
Cellectar Biosciences
CLRB
|
11.7 M | $ 3.63 | -3.97 % | $ 44.4 M | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
136 M | - | - | $ 2.18 B | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
714 M | $ 11.54 | 0.87 % | $ 746 M | USA |